Substance use & addiction journal · 2026
Impact of Assertive Outreach, Individual Involvement, and Significant Other Involvement on XR-NTX Adherence.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Karen, Wenzel Kevin, Thomas Julia, Fishman Marc
Аннотация
BACKGROUND AND OBJECTIVES: The current study investigates the roles of assertive outreach, individual participant involvement, and treatment significant other (TSO) involvement through the Medication Adherence Therapy: Psychosocial Leverage Using a Significant other (MAT-PLUS) intervention on extended-release naltrexone (XR-NTX) adherence for the treatment of opioid and/or alcohol use disorder (OUD/AUD).
METHODS: Participants receiving XR-NTX for OUD and/or AUD received 16 weeks of the MAT-PLUS intervention through a prior randomized controlled trial (RCT). Logs tracked XR-NTX adherence, treatment team outreach, and participant/family communications and sessions.
RESULTS: Of the contact types examined, only the number of family sessions attended significantly predicted next XR-NTX dose receipt (OR = 8.74, 95% CI [1.84, 54.41]) in n = 12 participants.
CONCLUSIONS: Family involvement is an important component of OUD/AUD treatment that may improve XR-NTX adherence.
CLINICAL TRIAL REGISTRATION: Treatment of opioid use: Medication Adherence Therapy (MAT-PLUS), https://clinicaltrials.gov/study/NCT03567356?term=MAT-PLUS&rank=1, NCT03567356.
METHODS: Participants receiving XR-NTX for OUD and/or AUD received 16 weeks of the MAT-PLUS intervention through a prior randomized controlled trial (RCT). Logs tracked XR-NTX adherence, treatment team outreach, and participant/family communications and sessions.
RESULTS: Of the contact types examined, only the number of family sessions attended significantly predicted next XR-NTX dose receipt (OR = 8.74, 95% CI [1.84, 54.41]) in n = 12 participants.
CONCLUSIONS: Family involvement is an important component of OUD/AUD treatment that may improve XR-NTX adherence.
CLINICAL TRIAL REGISTRATION: Treatment of opioid use: Medication Adherence Therapy (MAT-PLUS), https://clinicaltrials.gov/study/NCT03567356?term=MAT-PLUS&rank=1, NCT03567356.